Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment
- 22 January 2010
- journal article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 24 (1), 71-75
- https://doi.org/10.1007/s10557-009-6214-3
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Dalcetrapib: no off‐target toxicity on blood pressure or on genes related to the renin‐angiotensin‐aldosterone system in ratsBritish Journal of Pharmacology, 2009
- Extended-Release Niacin or Ezetimibe and Carotid Intima–Media ThicknessThe New England Journal of Medicine, 2009
- Response to Letter Regarding Article, “Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women”Circulation, 2009
- Novel Small Interfering RNA–Containing Solution Protecting Donor Organs in Heart TransplantationCirculation, 2009
- Macrovolt T-Wave Alternans and Polymorphic Ventricular TachycardiaCirculation, 2009
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsThe New England Journal of Medicine, 2007
- Design and Rationale of the ARBITER 6 Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)Cardiovascular Drugs and Therapy, 2007
- Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin TreatmentCirculation, 2003